Galapagos NV
Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen
B-2800
Tel: 32-15-34-29-00
Fax: 32-15-34-29-01
Website: http://www.galapagosgenomics.com/
519 articles with Galapagos NV
-
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis
7/24/2020
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca ® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis -- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- FOSTER CITY, Calif., & MECHELEN, Belgium--( BUSINESS WIRE )-- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronex
-
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
6/4/2020
Integrated Safety Analysis from the Phase 3 FINCH and Phase 2 DARWIN Programs Informs the Long-Term Safety Profile of Filgotinib in RA
-
Clinical Catch-Up: May 18-22
5/26/2020
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look. -
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
-
Galapagos and Ryvu Announce Research Collaboration - April 16, 2020
4/16/2020
Galapagos NV and Ryvu Therapeutics S.A. announced a collaboration focused on the discovery and development of novel small molecule drugs in inflammation.
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
-
While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.
-
Galapagos increases share capital through warrant exercises on 25 November 2019
11/25/2019
Galapagos NV announces a share capital increase arising from warrant exercises.
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
10/29/2019
MorphoSys AG announced the end of the clinical development program of MOR106 in atopic dermatitis.
-
The companies indicate that the decision was based on lack of efficacy, not any safety concerns.
-
HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV
10/16/2019
HitGen Inc. announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV.
-
Clinical Catch-Up: October 7-11
10/14/2019
It was a busy week for clinical trial announcements. Here’s a look. -
As Gilead Sciences and its development partner Galapagos NV eye filing a New Drug Application with the U.S. Food and Drug Administration for its JAK inhibitor filgotinib, the companies’ hopes have been boosted by new 52-week safety data.
-
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
8/15/2019
In early July, Gilead announced plans to submit a New Drug Application (NDA) for filgotinib for the treatment of RA in the United States before the end of the year.
-
Strong clinical progress in H1 and transformative collaboration with Gilead announced
7/25/2019
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
-
Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos' pipeline.
-
Gilead and Galapagos Enter Into Transformative Research and Development Collaboration
7/14/2019
Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration.
-
Galapagos increases share capital through warrant exercises on 20 June 2019
6/20/2019
Galapagos NV announces a share capital increase arising from warrant exercises.